BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.
Details
News Market Reaction – PHGE
The recorded move for PHGE in the trading session of this news was -0.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, August 16, 2021, at 8:00 a.m. EDT, to report second quarter 2021 financial results and provide business updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.), 1-809-406-247 (Israel) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Additional information is available at www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Assaf Oron
Chief Business Officer
+972 (54) 222-8901
assafo@biomx.com
Media:
LifeSci Advisors, LLC
John Mullaly
617-429-3548
Source: BiomX Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.